All Stories

  1. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis

    Article • Amyloid, September 2019, Taylor & Francis

    Eli Muchtar, Dr Nelson Leung, Shaji K Kumar

  2. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

    Article • Leukemia & Lymphoma, April 2019, Taylor & Francis

    Eli Muchtar, Amber Koehler

  3. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria

    Article • Amyloid, March 2019, Taylor & Francis

    Eli Muchtar, Shaji K Kumar

  4. The colorful landscape of multiple myeloma

    Article • Leukemia & Lymphoma, February 2019, Taylor & Francis

    Eli Muchtar

  5. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?

    Article • Amyloid, March 2018, Taylor & Francis

    Eli Muchtar, Shaji K Kumar

  6. Testicular plasmacytoma: unique location or circumstantial presentation?

    Article • Leukemia & Lymphoma, January 2018, Taylor & Francis

    Eli Muchtar

  7. Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation

    Article • Journal of the Neurological Sciences, August 2017, Elsevier

    Eli Muchtar

  8. Clinical trials evaluating potential therapies for light chain (AL) amyloidosis

    Article • Expert Opinion on Orphan Drugs, June 2017, Taylor & Francis

    Eli Muchtar

  9. Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer

    Article • Leukemia & Lymphoma, June 2017, Taylor & Francis

    Eli Muchtar

  10. Serial measurements of circulating plasma cells before and after induction therapy has an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation

    Article • Haematologica, May 2017, Ferrata Storti Foundation (Haematologica)

    Eli Muchtar

  11. Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

    Article • Journal of Internal Medicine, April 2017, Wiley

    Eli Muchtar

  12. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

    Article • Bone Marrow Transplantation, April 2017, Nature

    Eli Muchtar

  13. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics

    Article • Biology of Blood and Marrow Transplantation, April 2017, Elsevier

    Eli Muchtar

  14. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition

    Article • Annals of Medicine, March 2017, Taylor & Francis

    Shaji K Kumar, Dr Nelson Leung, Eli Muchtar

  15. First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis

    Article • Amyloid, March 2017, Taylor & Francis

    Eli Muchtar

  16. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

    Article • Amyloid, March 2017, Taylor & Francis

    Eli Muchtar

  17. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type

    Article • Amyloid, March 2017, Taylor & Francis

    Eli Muchtar

  18. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

    Article • Blood, January 2017, American Society of Hematology

    Eli Muchtar

  19. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

    Article • Leukemia, December 2016, Nature

    Eli Muchtar

  20. How I treat cryoglobulinemia

    Article • Blood, October 2016, American Society of Hematology

    Eli Muchtar

  21. High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges

    Article • Leukemia & Lymphoma, October 2016, Taylor & Francis

    Eli Muchtar

  22. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment

    Article • Blood, October 2016, American Society of Hematology

    Eli Muchtar

  23. Systemic Immunoglobulin Light Chain Amyloidosis–Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome

    Article • Mayo Clinic Proceedings, October 2016, Elsevier

    Eli Muchtar

  24. The Impact of Circulating Plasma Cells at Transplant on Survival in Multiple Myeloma in the Era of Novel Agents

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Eli Muchtar

  25. Systemic AL Amyloidosis Myopathy: Presentation, Diagnostic Pitfalls and Outcome

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Eli Muchtar

  26. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents

    Article • Bone Marrow Transplantation, August 2016, Nature

    Eli Muchtar

  27. Newer Therapies for Amyloid Cardiomyopathy

    Article • Current Heart Failure Reports, August 2016, Springer Science + Business Media

    Eli Muchtar

  28. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma

    Article • Leukemia & Lymphoma, July 2016, Taylor & Francis

    Eli Muchtar

  29. Autologous stem cell transplant for multiple myeloma patients 70 years or older

    Article • Bone Marrow Transplantation, July 2016, Nature

    Eli Muchtar

  30. Bone mineral density utilization in patients with newly diagnosed multiple myeloma

    Article • Hematological Oncology, June 2016, Wiley

    Eli Muchtar

  31. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type

    Article • Haematologica, June 2016, Ferrata Storti Foundation (Haematologica)

    Eli Muchtar

  32. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment

    Article • Therapeutic Advances in Hematology, June 2016, SAGE Publications

    Eli Muchtar

  33. The role of stem cell transplantation in Waldenstrom's macroglobulinemia

    Article • Best Practice & Research Clinical Haematology, June 2016, Elsevier

    Eli Muchtar

  34. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

    Article • Leukemia, May 2016, Nature

    Eli Muchtar

  35. Lenalidomide – the new melphalan?

    Article • Leukemia & Lymphoma, April 2016, Informa Healthcare

    Eli Muchtar

  36. A practical review on carfilzomib in multiple myeloma

    Article • European Journal Of Haematology, March 2016, Wiley

    Eli Muchtar

  37. Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis

    Article • Leukemia Research, February 2016, Elsevier

    Eli Muchtar

  38. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy

    Article • Acta Haematologica, January 2016, Karger Publishers

    Eli Muchtar

  39. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

    Article • British Journal of Haematology, November 2015, Wiley

    Dr Tamar Tadmor, Eli Muchtar

  40. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide

    Article • Cancer Genetics, November 2015, Elsevier

    Eli Muchtar

  41. Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment

    Article • European Journal Of Haematology, April 2015, Wiley

    Eli Muchtar

  42. First line and salvage therapy with total therapy 3-based treatment for multiple myeloma––An extended single center experience

    Article • Leukemia Research, December 2014, Elsevier

    Eli Muchtar

  43. Myeloma in Scar Tissue - An Underreported Phenomenon or an Emerging Entity in the Novel Agents' Era? A Single Center Series

    Article • Acta Haematologica, January 2014, Karger Publishers

    Eli Muchtar

  44. Posttransplantation Lymphoproliferative Disorder in Lung Transplant Recipients

    Article • Transplantation, October 2013, Wolters Kluwer Health

    Eli Muchtar

  45. Benchmarking inappropriate empirical antibiotic treatment

    Article • Clinical Microbiology and Infection, July 2013, Elsevier

    Eli Muchtar

  46. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission

    Article • Cochrane Database of Systematic Reviews, March 2013, Wiley

    Eli Muchtar

  47. The role of maintenance therapy in acute promyelocytic leukemia in first complete remission

    Article • January 2012, Wiley

    Eli Muchtar

  48. Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis

    Article • Antimicrobial Agents and Chemotherapy, August 2010, ASM Journals

    Eli Muchtar

  49. Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis

    Article • European Journal of Cancer, December 2009, Elsevier

    Eli Muchtar